Androgenetic alopecia (AGA) is the most common type of alopecia, affecting up to 80% of males and 50% of females. 1 It is a chronic, progressive, noncicatricial, androgen-dependent condition that affects genetically predisposed individuals, leading to progressive follicular miniaturization. Currently, only topical minoxidil and oral finasteride are approved for its treatment. 2 2 | C A S E REP ORT A 47-year-old healthy white male patient came to our clinic with a complaint of hair loss. On examination, the patient had diffuse thinning on his scalp hair and recession of the frontal and temporal hairline (Hamilton-Norwood Scale IV) without evidence of inflammation or scarring (Figure 1A). He had a positive family history of hair loss, and extensive laboratory analyses were unremarkable. We made the diagnosis of male pattern AGA, and we started the gold-standard treatment with minoxidil 5% topical solution twice daily and finasteride 1mg daily for 2 years, with improvement during this period. However, after that, the patient's clinical response stabilized and he requested hair transplantation. After a discussion of all treatment options, we added mesotherapy, a minimally invasive technique, to his previous treatment, postponing the need for an invasive procedure. The patient received 10 sessions of sterile injectable blend containing 1ml minoxidil 0,5%, 1ml finasteride 0,05%, 2ml biotin 5mg/ml, and 2ml D-panthenol 50mg/ml (Pineda®